FINWIRES · TerminalLIVE
FINWIRES

$CAMP

5 stories mentioning CAMPUpdated 47d ago

Every FINWIRES story that references CAMP, newest first.

Sectors

Sector Update: Healthcare Stocks Ease Late Afternoon

Healthcare stocks eased late Tuesday afternoon with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each decreasing 0.2%.The iShares Biotechnology ETF (IBB) also dropped 0.2%.In corporate news, Eli Lilly (LLY) acquired 4E Therapeutics, a neuroscience firm creating chronic-pain treatments. Lilly shares fell 1%.CAMP4 Therapeutics (CAMP) shares jumped 6.1% after JPMorgan upgraded the stock to overweight from neutral and raised its price target to $9 from $5.GSK (GSK) said Health Canada approved Exdensur for severe eosinophilic asthma, which is driven by elevated white blood cells, and for chronic rhinosinusitis with nasal polyps, a condition that causes blockage and inflammation. GSK shares eased 0.1%.Oncolytics Biotech (ONCY) shares climbed 11% after the company received a US patent covering the pelareorep manufacturing process into 2044.

$CAMP$GSK$LLY$ONCY
Sectors

Sector Update: Healthcare

Healthcare stocks edged lower late Tuesday afternoon, with the NYSE Healthcare Index decreasing 0.2% and the State Street Health Care Select Sector SPDR ETF (XLV) easing 0.1%.The iShares Biotechnology ETF (IBB) was down 0.%.In corporate news, CAMP4 Therapeutics (CAMP) shares jumped past 7% after JPMorgan upgraded the stock to overweight from neutral and raised its price target to $9 from $5.

$CAMP
Wire

CAMP4 Therapeutics Shares Rise After JPMorgan Upgrade

CAMP4 Therapeutics (CAMP) shares were up over 10% in Tuesday trading after JPMorgan upgraded the stock to overweight from neutral and raised its price target to $9 from $5.Trading volume stood at more than 788,000 shares, compared with a daily average of about 85,000.Price: $4.38, Change: $+0.42, Percent Change: +10.61%

$CAMP
Research

JPMorgan Upgrades CAMP4 Therapeutics to Overweight From Neutral, Adjusts PT to $9 From $5

CAMP4 Therapeutics (CAMP) has an average rating of buy and mean price target of $8.36, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

$CAMP
Research

Chardan Initiates Camp4 Therapeutics at Buy With $6.50 Price Target

Camp4 Therapeutics (CAMP) has an average rating of buy and mean price target of $7.79, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

$CAMP

Track with the FINWIRES app suite